GlaxoSmithKline: Tuberculosis trials

The registry lists 21 Tuberculosis studies with GlaxoSmithKline as lead sponsor. 1 are open to participants now and 14 have results posted.

Phase 1 8Phase 2 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Investigate the Repeat-dose Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With Ganfeborole in Female Participants of Non-childbearing PotentialRecruitingNCT07784894Phase 1
• A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of AgeCompletedNCT06354257Phase 1Results posted
• Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary TuberculosisCompletedNCT05382312Phase 2Results posted
• An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary TuberculosisCompletedNCT03557281Phase 2Results posted
• Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy SubjectsCompletedNCT03149848Phase 1Results posted
• First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy SubjectsCompletedNCT03075410Phase 1Results posted
• Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in AdultsCompletedNCT01755598Phase 2Results posted
• Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342CompletedNCT01669096Phase 2Results posted
• Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB DiseaseTerminatedNCT01424501Phase 2Results posted
• Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Immunodeficiency Virus (HIV)-Positive AdultsCompletedNCT01262976Phase 2Results posted
• Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy InfantsCompletedNCT01098474Phase 2Results posted
• Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Healthy HIV Negative AdolescentsCompletedNCT00950612Phase 2Results posted
• Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults.CompletedNCT00707967Phase 2Results posted
• Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy AdultsCompletedNCT00621322Phase 2Results posted
• Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy AdultsCompletedNCT00397943Phase 2Results posted
• A Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2556286 in Healthy Adult ParticipantsTerminatedNCT04472897Phase 1
• A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy SubjectsCompletedNCT01214993Phase 1
• Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative AdultsCompletedNCT00730795Phase 1
• Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic RegionCompletedNCT00600782Phase 2
• Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults.CompletedNCT00291889Phase 1
• Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-positive AdultsCompletedNCT00146744Phase 2